Arginine-rich cell penetrating peptides: Design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides

被引:47
作者
Abes, R. [1 ]
Arzumanov, A. [2 ]
Moulton, H. [3 ]
Abes, S. [1 ]
Ivanova, G. [2 ]
Gait, M. J. [2 ]
Iversen, P. [3 ]
Lebleu, B. [1 ]
机构
[1] Univ Montpellier 2, CNRS, UMR 5235, F-34095 Montpellier 5, France
[2] MRC, Mol Biol Lab, Cambridge CB2 2QH, England
[3] AVI Biopharma, Corvallis, OR 97333 USA
基金
英国医学研究理事会;
关键词
cell penetrating peptides; steric-block oligonucleotides; splicing correction; delivery;
D O I
10.1002/psc.979
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Rerouting the splicing machinery with steric-block oligonucleotides (ON) might lead to new therapeutic strategies in the treatment of diseases such as beta-thalassemia, Duchenne muscular dystrophy, or cancers. Interfering with splicing requires the sequence-specific and stable hybridization of RNase H-incompetent ON as peptide nucleic acids (PNA) or phosphorodiamidate morpholino oligomers (PMO). Unfortunately, these uncharged DNA mimics are poorly taken up by most cell types and conventional delivery strategies that rely on electrostatic interaction do not apply. Likewise, conjugation to cell penetrating peptides (CPPs) as Tat, Arg(9), Lys(8), or Pen leads to poor splicing correction efficiency at low concentration essentially because PNA- and PMO-CPP conjugates remain entrapped within endocytotic vesicles. Recently, we have designed an arginine-rich peptide (R-Ahx-R)(4) (with Ahx for aminohexanoic acid) and an arginine-tailed Penetratin derivative which allow sequence-specific and efficient splicing correction at low concentration in the absence of endosomolytic agents. Both CPPs are undergoing structure-activity relationship studies for further optimization as steric-block ON delivery vectors. Copyright (c) 2008 European Peptide Society and John Wiley & Sons. Ltd.
引用
收藏
页码:455 / 460
页数:6
相关论文
共 35 条
[1]  
ABES R, IN PRESS BIOCH SOC T
[2]   Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides [J].
Abes, S. ;
Moulton, H. ;
Turner, J. ;
Clair, P. ;
Richard, J. P. ;
Iversen, P. ;
Gait, M. J. ;
Lebleu, B. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :53-55
[3]   Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates [J].
Abes, S ;
Williams, D ;
Prevot, P ;
Thierry, A ;
Gait, MJ ;
Lebleu, B .
JOURNAL OF CONTROLLED RELEASE, 2006, 110 (03) :595-604
[4]  
ABES S, 2007, NUCLEIC ACIDS RES, V35, P1
[5]  
ABES S, 2007, HDB CELL PENETRATING, P29
[6]   Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents [J].
Abes, Said ;
Moulton, Hong M. ;
Clair, Philippe ;
Prevot, Paul ;
Youngblood, Derek S. ;
Wu, Rebecca P. ;
Iversen, Patrick L. ;
Lebleu, Bernard .
JOURNAL OF CONTROLLED RELEASE, 2006, 116 (03) :304-313
[7]   Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging [J].
Bergan, R ;
Hakim, F ;
Schwartz, GN ;
Kyle, E ;
Cepada, R ;
Szabo, JM ;
Fowler, D ;
Gress, R ;
Neckers, L .
BLOOD, 1996, 88 (02) :731-741
[8]   Progress in antisense technology [J].
Crooke, ST .
ANNUAL REVIEW OF MEDICINE, 2004, 55 :61-95
[9]   Chemical modifications to improve the cellular uptake of oligonucleotides [J].
Debart, Francoise ;
Abes, Said ;
Deglane, Gaelle ;
Moulton, Hong M. ;
Clair, Philippe ;
Gait, Michael J. ;
Vasseur, Jean-Jacques ;
Lebleu, Bernard .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (07) :727-737
[10]  
DEROSSI D, 1994, J BIOL CHEM, V269, P10444